In September 2022, the FDA has approved ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. 89% achieved transfusion independence with Hb > 8 g/dL. Common side effects: mommy comities, neutropenia, thrombocytopenia, anemia.
Studying for im boards! Thanks for the refresher.
Thanks do much Dr for thy strives to make everything clear
In September 2022, the FDA has approved ZYNTEGLO® (betibeglogene autotemcel), also known as beti-cel, a one-time gene therapy custom-designed to treat the underlying genetic cause of beta‑thalassemia in adult and pediatric patients who require regular red blood cell (RBC) transfusions. 89% achieved transfusion independence with Hb > 8 g/dL.
Common side effects: mommy comities, neutropenia, thrombocytopenia, anemia.
What a great video! A wonderful explanation for a complicated topic. I found this to be extremely helpful while studying for my board exam. Thanks!!
1ùķo
Thank you for this concise presentation
Thank you for the brief video!
You’re welcome!
Wonderful explanation sir
I'm an indian
Great Lectures ❤
Glad you like them!
Doctor can you explain how to diagnose cases according to CBC and HLPC